Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence (CAR-Bern 2013)

Insel Gruppe AG, University Hospital Bern

Status and phase: Completed; Phase 3

Conditions: Psychological Stress; Physiological Stress; Alcohol Craving

Treatments: Drug: Placebo Mannitol; Drug: Cortisol 20mg

Study type: Interventional

Funder types: Other

Identifiers

NCT02196142

068/14

Details and patient eligibility

About

To investigate the effects of cortisol on alcohol craving and stress reactivity in alcohol addicted subjects.

Randomized, double-blind, placebo-controlled, cross-over, single administration of study medication.

Study hypothesis: Cortisol has an inhibiting effect on alcohol craving and stress reactivity in alcohol dependent subjects.

Full description

Background

Alcohol dependence is a chronically and relapsing disorder with major impact on the persons psychological, physiological and social functioning. There is extensive evidence from animal and human studies pointing out the important role of addiction memory in the development and maintenance of the disorder.

Cognitive behavioural therapy (CBT) has proven its high effectiveness in the treatment for addictive disorders. A core element of CBT are exposure techniques that are comparable to extinction and habituation learning. The repeated exposure to alcohol related cues in the absence of alcohol ingestion will lead to extinction of conditioned responses, thus reducing the probability of relapse to alcohol taking behaviour.

Studies have shown that glucocorticoids impair memory retrieval in healthy subjects. In fact, the investigators could show that cortisol has a fear reducing effect in patients with post-traumatic stress disorder and in phobic patients, resulting particularly in reduced symptoms of anxiety and in reduced stress reactivity. Interestingly enough, pharmacologically induced high levels of glucocorticoids lowered the subjective feeling of anxiety and stress in situations activating per se the HPA-axis. Further it has been shown that the combined therapy of glucocorticoid administration and exposition based psychotherapy leads to better therapy outcome in patients with specific phobias.

Objective

The goal of this study is to examine the acute effects of glucocorticoids administration on alcohol craving and stress reactivity of abstinent alcohol dependent patients. On the basis of clinical research in anxiety disorders, the investigators expect that a pharmacologically increased cortisol level may impair the retrieval of addiction memory, which is indicated by less craving during the alcohol exposition, while exposition therapy enhances consolidation of corrective experiences. Similar to the research in anxiety patients, the investigators aim to examine whether cortisol administration could help improve the effects of exposition therapy in patients with alcohol dependence. The purpose is to decrease therapy duration through cortisol administration in addition to already well proven therapies and make the therapy more efficient as well as a factor in reducing healthcare costs.

Methods

Patients undergo two identical experimental sessions between the 6th and 8th week (one week in between) of their 12-week inpatient treatment program for alcohol dependence. The experiment takes place in the experimental rooms of the clinic Südhang between 1 and 6 pm. One hour before the confrontation with alcohol associated stimuli patients receive either 20mg of hydrocortisone or placebo (oral administration). The experiment consists of a computer based picture task (alcoholic and neutral pictures) and an in-vivo exposure task. Psychological (craving, stress, arousal) and physiological (heart rate, saliva cortisol) parameters are repeatedly measured over the course of the experiment.

Enrollment: 48 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Age ≥ 18
• Abstinent alcoholics in the 12-week in-patient program of the Clinic Südhang
• Abstained from alcohol for at least 6 weeks
• Voluntarily signed informed consent

Exclusion Criteria

• Co-morbid psychiatric disturbances (such as major depression, bipolar disorder, schizophrenia)
• Current medical conditions excluding participation (such as acute infectious disease)
• Recent history of systemic or topic glucocorticoid therapy
• Known hypersensitivity to the IMP under investigation (cortisol)
• Pregnancy, breast-feeding
• Inability to read and understand the participant's information
• Positive alcohol test according to breathalyser

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

48 participants in 2 patient groups

Cortisol first, Placebo second

Active Comparator group

Description:

Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)

Treatment:

Drug: Placebo Mannitol

Drug: Cortisol 20mg

Placebo first, Cortisol second

Active Comparator group

Description:

Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)

Treatment:

Drug: Placebo Mannitol

Drug: Cortisol 20mg